FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response 0.5

			of Section So(ii) of the investment Company Act of 1940								
1. Name and Addre		erson*	2. Issuer Name and Ticker or Trading Symbol MELA SCIENCES, INC. /NY [MELA]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
<u>Gulfo Joseph</u>	<u>l V</u>			X	Director	10% Owner					
(Last) C/O MELA SC	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 11/01/2011	- x	Officer (give title below) CEO & Pres	Other (specify below)					
50 SOUTH BU	1	EET, SUITE 1									
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)							
IRVINGTON	NY	10533		X	Form filed by One Rep	0					
(City)	(State)	(Zip)	-		Form filed by More tha Person	n One Reporting					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following Reported	Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130.4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	(
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		ansaction Derivative ode (Instr. Securities		6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option	\$3.75	11/01/2011 ⁽¹⁾	11/01/2011	A		540,000		11/01/2011	10/10/2018	Common Stock	540,000	\$0.00	900,000	D	

Explanation of Responses:

1. The option grant was made by the Issuer's Board of Directors on October 10, 2008, with vesting of the options conditioned upon approval by the U.S. Food and Drug Administration ("FDA") of the Issuer's pre-market approval ("PMA") application for MelaFind. The FDA approved the MelaFind PMA on November 1, 2011. In accordance with the SEC's rules and regulations, the option grant is now being reported by the Reporting Person; however, the option grant has already been reported by the Issuer in its reports previously filed with the SEC.

Remarks:

/s/ Philip DeBellis as attorneyin-fact for Joseph V. Gulfo

11/02/2011

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.